Fig. 3From: MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine designPredicted HLA-DRB1-binding INDEL mutant peptides in 147 lung adenocarcinoma patientsBack to article page